Company profile

Incorporated in
Fiscal year end
IRS number

INSY stock data



13 May 19
17 Jun 19
31 Dec 19


Company financial data Financial data

Quarter (USD) Mar 19 Dec 18 Sep 18 Jun 18
Revenue 7.63M 16.36M 18.35M 23.47M
Net income -123.84M -46.29M -30.49M -27.35M
Diluted EPS -1.66 -0.62 -0.41 -0.37
Net profit margin -1623% -283% -166% -117%
Operating income -122.11M -48.97M -30.82M -27.71M
Net change in cash 4.96M 10.71M 4.76M -2.46M
Cash on hand 36.51M 31.55M 20.85M 16.09M
Cost of revenue 4.58M 2.62M 2.38M 3.6M
Annual (USD) Dec 18 Dec 17 Dec 16 Dec 15
Revenue 82.08M 140.69M 242.28M 330.8M
Net income -124.51M -226.84M 7.59M 58.05M
Diluted EPS -1.68 -3.12 0.1 0.77
Net profit margin -152% -161% 3.13% 17.55%
Operating income -127.72M -219.03M 7.33M 90.46M
Net change in cash -447K -72.64M 25.13M 21.41M
Cash on hand 31.55M 32M 104.64M 79.52M
Cost of revenue 10.8M 20.64M 25.39M 28.85M

Financial data from company earnings reports

Financial report summary

Management Discussion
  • Net Revenue. Net revenue decreased $16.3 million, or 68.2%, to $7.6 million for the three months ended March 31, 2019, compared to $23.9 million for the three months ended March 31, 2018. The decrease in net revenue was primarily attributable to a 67.3% decrease in SUBSYS® shipments to our customers for the three months ended March 31, 2019 primarily due to reduced demand for SUBSYS®, as compared to the three months ended March 31, 2018, and a 1.6% decrease in net sales price due to changes in mix of prescribed dosages and changes in provisions for wholesaler discounts, patient discounts, rebates, and returns, partially offset by a price increase in January 2019. Provisions for patient discounts, wholesaler discounts, rebates, and returns were $0.9 million, $1.1 million, $3.3 million, and $0.8 million, respectively, for the three months ended March 31, 2019, compared to $1.7 million, $2.9 million, $6.6 million, and $3.4 million, respectively, for the three months ended March 31, 2018. The decrease in product sales allowances was primarily attributable to lower sales of SUBSYS® and a decrease in product returns during the three months ended March 31, 2019 as compared to the three months ended March 31, 2018. As we have previously disclosed, the continuing sensitivity by some health care professionals to prescribe, and pharmacies to dispense, opioids, scrutiny by third-party payers and governmental agencies, ongoing state and federal investigations, and media reports related thereto, will likely result in our inability to grow full-year SUBSYS® revenue for the remainder of 2019 when compared to 2018. In addition, for the same reasons, we anticipate that we will experience future declines in SUBSYS® revenue for the remainder of 2019 when compared to prior quarters in 2018. On May 9, 2019, the Company was notified by its logistics provider that such provider has ceased shipments to a specialty pharmaceutical retailer, which accounted for approximately 19% of our total product shipments for the three months ended March 31, 2019.  As a result, the Company is effectively precluded from shipping products to this specialty pharmaceutical retailer at this time.  Management is monitoring the situation and evaluating the impact of this cessation on its operations and future results. 
Content analysis ?
H.S. freshman Good
New words: accelerated, Alaska, Andrece, Andrew, Baltimore, Bankruptcy, Beach, borrow, borrowing, Boynton, building, ceased, certify, cessation, CFC, clarification, claw, clawback, collateralize, collateralized, confidence, convey, Cora, craving, criteria, Daisey, Dakota, Dann, defrauded, DeRuiter, Dianne, disorder, doubt, effort, environment, equal, ESPP, Essex, expertise, explanatory, Feinstein, felony, Fifteenth, Foxx, global, Goodell, Goskonda, Gotham, Greenwald, Hardin, high, highly, HMO, Housley, IBR, Idaho, impending, implicit, inception, incremental, indefinitely, irrevocable, Jennifer, jury, Kenneth, kickback, kind, lab, Lazard, learned, Leech, lift, loan, long, lose, Markman, Marysol, Medina, Merchandising, Mitchell, Motahari, multistate, Nance, Nicholson, NIDA, NIH, nuisance, obsolescence, older, Orange, Palm, Paula, Pearlman, persistent, Peter, plea, power, preliminary, Progressive, quality, readily, relapse, remote, rent, reorganization, reorganize, replaced, retention, ROU, Saeed, Santiago, scrap, se, senior, situated, situation, SLC, Sorrentino, space, speculative, Stefurak, succeeding, Sun, suspended, tagged, tenant, therapeutic, therapy, tolerant, truth, twelve, unamortized, unavoidable, unnecessarily, upheld, Venkat, vi, voluntary, Warren, Wisconsin
Removed: accept, acceptable, acceptance, accumulate, achievement, acquire, addressed, adequate, admit, adult, AG, analyzed, approve, AVC, aware, balanced, beneficial, branded, Bulletin, cannabinoid, capability, capacity, Carolyn, charitable, charter, chemical, choose, classification, CMS, collaborative, collection, combined, communicate, competing, conform, consistently, constructed, Conversely, convertible, Cook, correct, cover, covering, critical, damage, declaration, Decree, deductibility, deletion, delivered, demonstrate, depend, dependence, dependent, detail, detection, differentiating, dilution, dilutive, disclose, disclosing, discontinuance, dispensing, distribute, diversity, dosage, earlier, efficacy, efficient, eliminate, enable, enforcing, ensure, environmental, epilepsy, equipped, ESI, establishing, evolving, excluded, existed, expanded, expedient, expenditure, facilitated, familiarity, favorable, field, fluctuate, fluctuation, force, foreseeable, formulary, foundation, fourth, fraudulently, fulfilled, funding, heightened, higher, hire, Humana, immaterial, important, imposed, inaccurate, increasingly, incurring, induced, infrastructure, inherent, initiating, initiative, instance, instituted, insufficient, integrated, intention, international, interruption, invest, invoicing, joint, landscape, large, leasing, led, legislation, lengthy, lessor, light, list, macro, manage, managed, manner, Marinol, Markland, migration, minimal, misprescribing, mission, misuse, modification, Mylan, nasdaq, natural, NDA, NeoPharm, occurring, ODOJ, officially, offsetting, opened, opening, operate, oversee, past, pathway, payer, paying, PBM, penetrate, perception, pharmacological, pipeline, planned, preparing, prescriber, prescribing, pressure, privacy, procedural, prohibited, project, promised, proportion, prosecuting, protocol, provisional, publicity, published, pure, realize, reclassified, recognizing, reducing, registrant, reimburse, reimbursement, released, relinquish, remediating, repeat, reputational, resolve, restrict, retrospective, Robert, satisfaction, scale, setting, solution, sourced, staffing, stage, stake, starter, stockholder, storage, submitted, substantially, suffering, sufficient, supportive, target, Technical, technological, thereon, titrated, traditional, transition, transportation, trend, turn, undesirable, unique, unpredictability, volume, working, worldwide, worsen, wrongdoing, wrongfully